WO2019240126A1 - Composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que promoteur de production de monoamine - Google Patents

Composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que promoteur de production de monoamine Download PDF

Info

Publication number
WO2019240126A1
WO2019240126A1 PCT/JP2019/023079 JP2019023079W WO2019240126A1 WO 2019240126 A1 WO2019240126 A1 WO 2019240126A1 JP 2019023079 W JP2019023079 W JP 2019023079W WO 2019240126 A1 WO2019240126 A1 WO 2019240126A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
monoamine
mesenchymal stem
cells
stem cells
Prior art date
Application number
PCT/JP2019/023079
Other languages
English (en)
Japanese (ja)
Inventor
漆畑　直樹
勝幸 隠岐
Original Assignee
株式会社バイオミメティクスシンパシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社バイオミメティクスシンパシーズ filed Critical 株式会社バイオミメティクスシンパシーズ
Priority to CN201980006018.3A priority Critical patent/CN111479576A/zh
Publication of WO2019240126A1 publication Critical patent/WO2019240126A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Le problème décrit par la présente invention concerne une composition pharmaceutique qui favorise la production de neurotransmetteurs de monoamine dans un corps vivant possédant du sang et du fluide cérébral. La solution selon l'invention porte sur une composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que constituant efficace, qui a pour fonction de favoriser la production de neurotransmetteurs de monoamine et de produits métaboliques principaux correspondants dans le sang, le fluide cérébral, etc. dans un corps vivant. Des exemples de monoamine comprennent la sérotonine et la noradrénaline et des exemples des produits métaboliques de monoamine comprennent l'acide 5-hydroxyindolacétique (5-HIAA) et le 3-méthoxy-4-hydroxyphényléthylèneglycol (MHPG).
PCT/JP2019/023079 2018-06-13 2019-06-11 Composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que promoteur de production de monoamine WO2019240126A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980006018.3A CN111479576A (zh) 2018-06-13 2019-06-11 作为单胺产生促进剂的包含间充质干细胞的医药组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018113184A JP6829225B2 (ja) 2018-06-13 2018-06-13 モノアミン産生増加剤としての間葉系幹細胞を含む医薬組成物
JP2018-113184 2018-06-13

Publications (1)

Publication Number Publication Date
WO2019240126A1 true WO2019240126A1 (fr) 2019-12-19

Family

ID=68841976

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/023079 WO2019240126A1 (fr) 2018-06-13 2019-06-11 Composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que promoteur de production de monoamine

Country Status (3)

Country Link
JP (1) JP6829225B2 (fr)
CN (1) CN111479576A (fr)
WO (1) WO2019240126A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6497827B1 (ja) * 2018-07-17 2019-04-10 株式会社 バイオミメティクスシンパシーズ エイコサノイド産生促進剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012100662A (ja) * 2011-12-05 2012-05-31 Sapporo Medical Univ 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2015521630A (ja) * 2012-06-26 2015-07-30 ラスティー プロパティー ホールディングス プロプライエタリー リミテッド 頭痛の頻度および／または重症度を下げるための組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257030A1 (en) * 2000-04-12 2001-10-30 Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
WO2017165426A1 (fr) * 2016-03-22 2017-09-28 The Regents Of The University Of California Compositions et méthodes pour favoriser la cicatrisation des plaies
KR101816246B1 (ko) * 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012100662A (ja) * 2011-12-05 2012-05-31 Sapporo Medical Univ 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2015521630A (ja) * 2012-06-26 2015-07-30 ラスティー プロパティー ホールディングス プロプライエタリー リミテッド 頭痛の頻度および／または重症度を下げるための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PANG, XIAODONG ET AL.: "Human Umbilical Cord Mesenchymal Stem Cell Transplantation for the Treatment of Chronic Discogenic Low Bach Pain", PAIN PHYSICIAN, vol. 17, 1 July 2014 (2014-07-01), pages E525 - E530, XP055664218, ISSN: 2150-1149 *
SHWARTZ, AMIT ET AL.: "Therapeutic Effect of Astroglia - like Mesenchymal Stem Cells Expressing Glutamate Transporter in a Genetic Rat Model of Depression", THERANOSTICS, vol. 7, no. 10, 6 July 2017 (2017-07-06), pages 2690 - 2703, XP055664213, ISSN: 1838-7640, DOI: 10.7150/thno.18914 *
YE, YING ET AL.: "The treatment of spinal cord injury in rats using bone marrow-derived neural- like cells induced by cerebrospinal fluid", NEUROSCIENCE LETTERS, vol. 666, 20 December 2017 (2017-12-20), pages 85 - 91, XP085344580, ISSN: 0304-3940, DOI: 10.1016/j.neulet.2017.12.043 *

Also Published As

Publication number Publication date
JP6829225B2 (ja) 2021-02-10
CN111479576A (zh) 2020-07-31
JP2019214534A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
US10406180B2 (en) Composition including stem cell-derived microvesicles for promoting neurogenesis
JP5871865B2 (ja) 神経前駆細胞又は神経幹細胞の神経細胞への分化及び増殖の誘導方法、分化及び増殖誘導用組成物、及び薬学的製剤
US11040072B2 (en) Composition for inducing beige adipocyte differentiation containing exosome derived from stem cells
CN109562129A (zh) 含有从脂肪来源的干细胞提取的外排体作为活性成分的用于预防或治疗肺纤维化的组合物
Mao et al. Endoplasmic reticulum stress contributes to nociception via neuroinflammation in a murine bone cancer pain model
JP7246569B2 (ja) 幹細胞由来エクソソーム生成促進及び幹細胞能増強用組成物
US9688733B2 (en) Method for treating spinal cord injury using HMGB1 fragment
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
CN101553565A (zh) 从血液特别是外周血扩增成体干细胞的方法及在医药领域的相关应用
US20150359849A1 (en) Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
KR20190063453A (ko) 줄기세포 유래 엑소좀 생성 촉진용 조성물
WO2019240126A1 (fr) Composition pharmaceutique contenant des cellules souches mésenchymateuses en tant que promoteur de production de monoamine
JP2023026291A (ja) カンナビノイド組成物、及びパーキンソン病、アルツハイマー病などの神経変性疾患を治療する薬物の製造におけるその応用
CN112023050A (zh) 一种调节巨噬细胞极化状态的方法
JPWO2020004014A1 (ja) エルゴチオネイン、アスコルビン酸２−グルコシド、アスコルビン酸、およびそれらの組み合わせの筋分化促進作用
WO2016041192A1 (fr) Utilisation de ligustilide
JP6497827B1 (ja) エイコサノイド産生促進剤
JP2024518396A (ja) 三次元スフェロイド型細胞凝集体に由来の細胞外小胞を含む神経再生促進組成物
WO2023199829A1 (fr) Microparticules, médicament prophylactique ou médicament thérapeutique pour la dépression, et méthode pour atténuer la dépression
WO2023190267A1 (fr) Particule fine, médicament prophylactique ou médicament thérapeutique contre la maladie de parkinson, et procédé d'amélioration de la maladie de parkinson
JP7486328B2 (ja) 神経突起伸長促進剤、神経細胞の樹状突起発現促進剤、及び神経栄養因子様作用物質
JP7447803B2 (ja) アドビリン機能促進剤としての環状アミン誘導体並びに新規環状アミン誘導体及びその医薬用途
WO2022113667A1 (fr) Agent de transfert intra-snc contenant des microglies, agent thérapeutique contre une maladie du snc comprenant celui-ci, animal à introduction de microglies et son procédé de production
Yuan et al. Differentiation of rat embryonic cerebral cortex neural stem cells cultured by erythropoietin in vitro
WO2019135407A1 (fr) Méthode de traitement et/ou de prévention d'une douleur neuropathique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19820297

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19820297

Country of ref document: EP

Kind code of ref document: A1